Intravesical chemotherapy in BCG waiting period may prolong time to recurrence for high-risk NMIBC patients
Abstract Purpose This study aimed to determine whether administering intravesical chemotherapy (IVC) during the Bacillus Calmette - Guérin (BCG) waiting period after the second TURBT improves the recurrence-free survival (RFS) of patients with non - muscle - invasive bladder cancer (NMIBC). Methods...
Saved in:
| Main Authors: | Zhen Li, Zewei Wang, Jiyue Wu, Feilong Zhang, Lijian Gan, Wei Wang, Hailong Li, Ling Gu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-13705-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Intravesical BCG: Possible Protective Impact Against COVID-19 in NMIBC Patients
by: Gabriel GLUCK, et al.
Published: (2020-06-01) -
Urinary microbiota changes among NMIBC patients during BCG therapy: comparing BCG responders and non-responders
by: Toni Boban, et al.
Published: (2025-03-01) -
Real‐world oncological and toxicity outcomes with the Moscow strain of intravesical BCG for non‐muscle invasive bladder cancer—Implications for global shortage
by: Amandeep Arora, et al.
Published: (2025-06-01) -
Intravesical VSVd51-GM-CSF virotherapy is superior to BCG in treating bladder cancer in preclinical and translational models
by: Lauren Daniel, et al.
Published: (2025-09-01) -
Does the Decrease in Neutrophil-lymphocyte Ratio after BCG Treatment Be a Prognostic Marker for NMIBC?
by: Aykut Başer
Published: (2020-12-01)